Proton-Shuttling Lichen Compound Usnic Acid Affects Mitochondrial and Lysosomal Function in Cancer Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Bessadottir, Margret ^a   Egilsson, Mar ^a   Einarsdottir, Eydis ^a   Magnusdottir, Iris H ^a   Ogmundsdottir, Margret H ^a   Omarsdottir, Sesselja ^a   Ogmundsdottir, Helga M ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; USNIC ACID;

ACIDIFICATION; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CELL STRESS; CONTROLLED STUDY; DEGRADATION; DRUG ACTIVITY; ENERGY METABOLISM; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; LYSOSOME; MITOCHONDRION; PROTON TRANSPORT;

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; BENZOFURANS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; LICHENS; LYSOSOMES; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA; NEOPLASMS; PHAGOSOMES; PROTONS; SIGNAL TRANSDUCTION; VACUOLES;

EID: 84870834608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051296     Document Type: Article

References (37)

1. Nash TH, editor (1996) Lichen Biology. Cambridge: Cambridge University Press.
2. Ingolfsdottir K, (2002) Usnic acid. Phytochemistry 61: 729-736.
3. Kupchan SM, Kopperman HL, (1975) l-usnic acid: tumor inhibitor isolated from lichens. Experientia 31: 625.
4. Takai M, Uehara Y, Beisler JA, (1979) Usnic acid derivatives as potential antineoplastic agents. J Med Chem 22: 1380-1384.
5. Cardarelli M, Serino G, Campanella L, Ercole P, De Cicco Nardone F, et al. (1997) Antimitotic effects of usnic acid on different biological systems. Cell Mol Life Sci 53: 667-672.
6. Bezivin C, Tomasi S, Rouaud I, Delcros JG, Boustie J, (2004) Cytotoxic activity of compounds from the lichen: Cladonia convoluta. Planta Med 70: 874-877.
7. Koparal AT, Tuylu BA, Turk H, (2006) In vitro cytotoxic activities of (+)-usnic acid and (-)-usnic acid on V79, A549, and human lymphocyte cells and their non-genotoxicity on human lymphocytes. Nat Prod Res 20: 1300-1307.
8. Mayer M, ONeill MA, Murray KE, Santos-Magalhaes NS, Carneiro-Leao AM, et al. (2005) Usnic acid: a non-genotoxic compound with anti-cancer properties. Anticancer Drugs 16: 805-809.
9. Joseph A, Lee T, Moland CL, Branham WS, Fuscoe JC, et al. (2009) Effect of (+)-usnic acid on mitochondrial functions as measured by mitochondria-specific oligonucleotide microarray in liver of B6C3F1 mice. Mitochondrion 9: 149-158.
10. Han D, Matsumaru K, Rettori D, Kaplowitz N, (2004) Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 67: 439-451.
11. Gogvadze V, Orrenius S, Zhivotovsky B, (2008) Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18: 165-173.
12. Einarsdottir E, Groeneweg J, Bjornsdottir GG, Harethardottir G, Omarsdottir S, et al. (2010) Cellular mechanisms of the anticancer effects of the lichen compound usnic acid. Planta Med 76: 969-974.
13. Eskelinen EL, Prescott AR, Cooper J, Brachmann SM, Wang L, et al. (2002) Inhibition of autophagy in mitotic animal cells. Traffic 3: 878-893.
14. Mancias JD, Kimmelman AC, (2011) Targeting autophagy addiction in cancer. Oncotarget 2: 1302-1306.
15. Lozy F, Karantza V (2012) Autophagy and cancer cell metabolism. Semin Cell Dev Biol.
16. Kaushik S, Singh R, Cuervo AM, (2010) Autophagic pathways and metabolic stress. Diabetes Obes Metab 12 (Suppl 2): 4-14.
17. Klionsky DJ, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, et al. (2003) A unified nomenclature for yeast autophagy-related genes. Dev Cell 5: 539-545.
18. Shackelford DB, Shaw RJ, (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575.
19. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, et al. (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17: 654-666.
20. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ, (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6: 1791-1797.
21. Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, et al. (2004) The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 10: 3583-3589.
22. Brooks SC, Locke ER, Soule HD, (1973) Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248: 6251-6253.
23. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728.
24. Kimura S, Noda T, Yoshimori T, (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3: 452-460.
25. Hanahan D, Jessee J, Bloom FR, (1991) Plasmid transformation of Escherichia coli and other bacteria. Methods Enzymol 204: 63-113.
26. Ulivieri C, (2010) Cell death: insights into the ultrastructure of mitochondria. Tissue Cell 42: 339-347.
27. Abo-Khatwa AN, al-Robai AA, al-Jawhari DA, (1996) Lichen acids as uncouplers of oxidative phosphorylation of mouse-liver mitochondria. Nat Toxins 4: 96-102.
28. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.
29. Zheng YT, Shahnazari S, Brech A, Lamark T, Johansen T, et al. (2009) The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. J Immunol 183: 5909-5916.
30. Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, et al. (2010) Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol Vis Sci 51: 6030-6037.
31. Griffiths G, Hoflack B, Simons K, Mellman I, Kornfeld S, (1988) The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell 52: 329-341.
32. Webb BA, Chimenti M, Jacobson MP, Barber DL, (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11: 671-677.
33. Faivre S, Kroemer G, Raymond E, (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
34. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, et al. (2010) Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 103: 649-655.
35. Ding WX, Ni HM, Gao W, Chen X, Kang JH, et al. (2009) Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 8: 2036-2045.
36. Ndolo RA, Jacobs DT, Forrest ML, Krise JP, (2010) Intracellular Distribution-based Anticancer Drug Targeting: Exploiting a Lysosomal Acidification Defect Associated with Cancer Cells. Mol Cell Pharmacol 2: 131-136.
37. Gong Y, Wang Y, Chen F, Han J, Miao J, et al. (2000) Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leuk Res 24: 769-774.